# The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

> **NCT06504186** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- B-ALL

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT06504186
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2026-06
- **Final completion:** 2026-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504186, "The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06504186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*